DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» ESHAP
ESHAP
Hodgkin Lymphoma Treatment Regimens
R-Eshap Patient Information Leaflet Keep All Medicine
Approved Amendment 2 07 May 2019 Confidentiality Notice This Document Contains Confidential Information of Amgen Inc
ESHAP and R-ESHAP
Diffuse Large B-Cell Lymphoma (Part 1 of 5)
Therapy-Related Acute Myeloid Leukemia in Patients with Lymphoma: a Report of Four Cases and Review of the Literature
Cisplatin-Based Chemotherapy of Human Cancers
Study Design
Zevalin Clinical Trial Protocol
The Role of Glucocorticoids in the Treatment of Non-Hodgkin Lymphoma
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: from Dose Puzzle to Pharmacogenomic Biomarkers
Rapid Infusion of Rituximab with Or Without Steroid-Containing Chemotherapy: 1-Yr Experience in a Single Institution
ESHAP Plus G-CSF As an Effective Peripheral Blood
Open the Guidelines for Febrile Neutropenia
Public Assessment Report
ESHAP (Etoposide, Methylprednisolone, Cytarabine and Cisplatin) Treatment and Stem Cell Collection
Policy Drug(S) Change Brief Description of Policy Change
Autologous Hematopoietic Stem Cell Transplantation As Salvage
Top View
ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin’S Lymphoma: a Single Center Experience
Efficacy of ESHAP Regimen in Transplant Ineligible Patients with Relapsed/Refractory T-Cell Lymphoma
NCCN Guidelines for Patients Diffuse Large B-Cell Lymphoma
Case Report Thrombotic Microangiopathy of Hyperacute Onset After Autologous Peripheral Blood Stem Cell Transplantation in Malignant Lymphoma
Serum Potassium, Calcium and Magnesium in Patients
Chemotherapy Regimen: ESHAP
Trend of Salvage Treatment in Diffuse Large B Cell Lymphoma in the Outpatient Chemotherapy Era
Progenitor Cell Mobilization Effect of Prior Chemotherapy on Hematopoietic Stem Cell Mobilization
Non-Hodgkin's Lymphoma Phase II Study of a High-Dose Ifosfamide
Strategies to Improve Outcomes of Autologous Hematopoietic Cell Transplant in Lymphoma
Hodgkin Lymphoma and Chronic Lymphocytic Leukemia)
Addition of 3-Day Aprepitant to Ondansetron and Dexamethasone for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting Among
Cisplatin: Drug Information
Symbio Receives Approval for Use of TREAKISYM® in Combination With
CHMP Assessment Report
Rituximab and ESHAP As Second-Line Therapy for Relapsed Or Primary Refractory Diffuse Large B Cell Lymphoma: the Experience of a Single Center in Korea
In Multiple Human Lymphoma Xenograft Models Tontanai Numbenjapon,1 Jianyi Wang,1 David Colcher,1 Thomas Schluep,4 Marke
Antibody–Drug Conjugates: a Comprehensive Review Puregmaa Khongorzul1, Cai Jia Ling1, Farhan Ullah Khan2, Awais Ullah Ihsan3, and Juan Zhang1